This is a standard Form 3 filing by a major pre-IPO investor (OrbiMed) following ADARx's IPO. No actionable trading signal — monitor future Form 4 filings for any open-market sales or purchases by this insider.
Price Chart
Executive Summary
Carl L. Gordon, Ph.D., CFA, a representative of OrbiMed Advisors, filed an initial Statement of Beneficial Ownership (Form 3) with ADARx Pharmaceuticals, Inc., reporting indirect beneficial ownership of shares of common stock via convertible preferred stock holdings through OrbiMed affiliated entities. The filing is a routine Section 16 compliance requirement following ADARx's IPO and does not convey any new trading activity or change in ownership.
Key Facts
- Form 3 filed by Carl L. Gordon, Ph.D., CFA, reporting ownership through OrbiMed Private Investments VII, LP and OrbiMed Israel Partners II, L.P.
- Reports indirect beneficial ownership of 10,690,530 shares of Common Stock (via Series A Preferred), 7,127,019 shares (Series A Preferred), 2,000,962 shares (Series B Preferred), 1,333,975 shares (Series B Preferred), 769,601 shares (Series B-1 Preferred), 513,067 shares (Series B-1 Preferred), 564,187 shares (Series C Preferred), and 256,448 shares (Series C Preferred), all on a converted basis.
- Each share of Preferred Stock automatically converts on a 1-for-1.1717 basis into Common Stock upon closing of the IPO.
- The reporting person disclaims beneficial ownership for purposes of Rule 16a-1(a), except for pecuniary interest.
Financial Impact
No financial impact; the filing is a routine initial ownership disclosure with no transaction or change in position.
Risk Factors
- Potential future insider selling if lock-up expires, but no indication from this filing alone.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001282930-26-000014 |
| Document: 0001282930-26-000014-index-headers.html | 0001282930-26-000014 |
| Document: 0001282930-26-000014-index.html | 0001282930-26-000014 |
| Document: 0001282930-26-000014.txt | 0001282930-26-000014 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | SC 13G | $17.63 $17.68 | ▲ +0.28% | ▼ −0.05% | $18.13 (+2.84%) |
Oct 5, 2026 22d ago | SC 13D | $18.58 $17.33 | ▼ −6.73% | ▼ −6.49% | $18.13 (−2.42%) |
Oct 2, 2026 25d ago | SC 13D | $19.05 $18.58 | ▼ −2.47% | ▼ −3.02% | $18.13 (−4.83%) |
Oct 1, 2026 26d ago | Press Release | $18.25 $19.05 | ▲ +4.38% | ▲ +3.71% | $18.13 (−0.66%) |
Oct 1, 2026 26d ago | SC 13G | $18.25 $19.05 | ▲ +4.38% | ▲ +3.71% | $18.13 (−0.66%) |
Sep 30, 2026 27d ago | Insider Cluster | $19.54 $18.25 | ▼ −6.60% | ▼ −7.34% | $18.13 (−7.22%) |
Sep 29, 2026 27d ago | Insider Cluster | $19.94 $19.54 | ▼ −2.01% | ▼ −2.18% | $18.13 (−9.08%) |
Sep 25, 2026 4w ago | 424B4 | $20.09 $20.64 | ▲ +2.71% | ▲ +2.90% | $18.13 (−9.76%) |
Sep 25, 2026 4w ago | EFFECT | $19.35 $20.09 | ▲ +3.82% | ▲ +4.57% | $18.13 (−6.30%) |
Sep 24, 2026 4w ago | Press Release | $19.35 $20.09 | ▲ +3.82% | ▲ +4.57% | $18.13 (−6.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers